Log in

Relevant bibliographies by topics / Incremental costeffectiveness ratio / Journal articles

To see the other types of publications on this topic, follow the link: Incremental costeffectiveness ratio.

Journal articles on the topic 'Incremental costeffectiveness ratio'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 18 journal articles for your research on the topic 'Incremental costeffectiveness ratio.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bezdenezhnykh, T. P., N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, and V. V. Omelyanovsky. "International experience in determining the cost-effectiveness thresholds." PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology 11, no. 4 (2019): 73–80. http://dx.doi.org/10.17749/2070-4909.2018.11.4.073-080.

Full text

Abstract:

The article reviews international methodological guidelines, regulatory documents and existing approaches to the determination of the costeffectiveness threshold (CeT), also known as the willingness-to-pay threshold (WTP), the threshold value of the incremental cost-effectiveness ratio (ICeR), in europe (england and Wales, Scotland, Ireland, France, Belgium, Denmark, the netherlands, Germany, Sweden, Finland, norway, Poland), America (the USA, Canada, Brazil), Asia (Japan, South korea, Taiwan, Thailand), in Australia and new Zealand. The CeT is commonly used to rationalize decision-making in h

APA, Harvard, Vancouver, ISO, and other styles

2

Gensichen, Jochen, Juliana J. Petersen, Michael Von Korff, et al. "Cost-effectiveness of depression case management in small practices." British Journal of Psychiatry 202, no. 6 (2013): 441–46. http://dx.doi.org/10.1192/bjp.bp.112.118257.

Full text

Abstract:

BackgroundCase management undertaken by healthcare assistants in small primary care practices is effective in improving depression symptoms and adherence in patients with major depression.AimsTo evaluate the cost-effectiveness of depression case management by healthcare assistants in small primary care practices.MethodCost-effectiveness analysis on the basis of a pragmatic randomised controlled trial (2005-2008): practice-based healthcare assistants in 74 practices provided case management to 562 patients with major depression over 1 year. Our primary outcome was the incremental costeffectiven

APA, Harvard, Vancouver, ISO, and other styles

3

Faccioli, Niccolò, Elena Santi, Giovanni Foti, Pierpaolo Curti, and Mirko D'Onofrio. "Cost-effectiveness analysis of short biparametric magnetic resonance imaging protocol in men at risk of prostate cancer." Archivio Italiano di Urologia e Andrologia 94, no. 2 (2022): 160–65. http://dx.doi.org/10.4081/aiua.2022.2.160.

Full text

Abstract:

Objectives: To compare the cost-effectiveness of a short biparametric MRI (BP-MRI) with that of contrast-enhanced multiparametric MRI (MP-MRI) for the detection of prostate cancer in men with elevated prostatespecific antigen (PSA) levels. Materials and methods: We compared two diagnostic procedures for detection of prostate cancer (Pca), BP-MRI and MP-MRI, in terms of quality-adjusted life years (QALY), incremental costeffectiveness ratio (ICER) and net monetary benefit (NMB) for a hypothetical cohort of 10,000 patients. We compared two scenarios in which different protocols would be used for

APA, Harvard, Vancouver, ISO, and other styles

4

Lee, Yeon-Woo, Sun-Hong Kwon, Na-Hyun Kim, and Eui-Kyung Lee. "Cost-effectiveness of Combination Therapy of Anticoagulants/antiplatelets with Proton Pump Inhibitors: A Systematic Review." Yakhak Hoeji 66, no. 5 (2022): 292–301. http://dx.doi.org/10.17480/psk.2022.66.5.292.

Full text

Abstract:

Anticoagulants/antiplatelets are effective in preventing cardiovascular diseases (CVDs). However, as an adverse effect, the risk of upper gastrointestinal bleeding (UGIB) leads to additional costs due to increased treatment and decreased quality of life. Accordingly, the administration of proton pump inhibitors (PPI) is recommended to prevent UGIB. We conducted a systematic review of economic evaluations of PPI co-therapy for patients taking long-term anticoagulants/ antiplatelets to prevent CVDs to examine the cost effectiveness of PPI co-therapy. We searched literature from PubMed and EMBASE

APA, Harvard, Vancouver, ISO, and other styles

5

Jaszewski, B., X. Gao, P. Reddy, et al. "Cost effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Canada." Journal of Clinical Oncology 25, no. 18_suppl (2007): 5111. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5111.

Full text

Abstract:

5111 Background: Sorafenib is an oral multi-kinase inhibitor that targets tumour cell proliferation and tumour angiogenesis. In the TARGETs study (phase III trial), sorafenib plus best supportive care (BSC) significantly prolonged progression-free survival (PFS) compared with BSC alone (P<0.000001) in patients with advanced renal cell carcinoma (RCC). The objective of this study was to evaluate the costeffectiveness of sorafenib plus BSC versus BSC alone in advanced RCC from a Canadian provincial Ministry of Health perspective. Methods: A Markov model was developed to project the lifetime s

APA, Harvard, Vancouver, ISO, and other styles

6

Nayak, Laxmipriya, Suhasini Dehury, Subhalaxmi Rautray, Lorika Sahu, and Debadutta Sahu. "Comparative analysis of efficacy, safety, and cost-effectiveness of betahistine alone, caroverine alone, and caroverine plus ginkgo biloba in moderate tinnitus." Indian Journal of Pharmacology 56, no. 6 (2024): 379–85. https://doi.org/10.4103/ijp.ijp_695_24.

Full text

Abstract:

Abstract: BACKGROUND: Tinnitus or “phantom sound” continues to be a significant health problem without a uniformly accepted treatment. Numerous pharmaceutical options have been investigated, but satisfactory results are yet to be obtained. OBJECTIVES: The objectives of this study were to study and compare the efficacy, safety, and cost-effectiveness of caroverine alone, caroverine combined with ginkgo biloba and betahistine alone in patients of moderate tinnitus. MATERIALS AND METHODS: In this prospective, observational, hospital-based study, wherein 72 patients were distributed equally across

APA, Harvard, Vancouver, ISO, and other styles

7

Lertsirimunkon, Jadesada. "Costs per DALYs Averted of Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccine in Elderly Population in Thailand." Siriraj Medical Journal 73, no. 4 (2021): 259–67. http://dx.doi.org/10.33192/smj.2021.34.

Full text

Abstract:

Objective: Influenza is an infection of the respiratory system with a high annual incident rate. Influenza vaccine can reduce the severity of influenza and prevent transmission of the virus. Influenza vaccines in Thailand are the Trivalent Influenza Vaccine (TIV) and the Quadrivalent Influenza Vaccine (QIV). The cost and the effectiveness of the QIV in preventing transmission of the virus are greater than the TIV. Until now, no studies have been conducted to compare the economic impact of using QIV or TIV. This study aimed to evaluate the economic effects of using QIV versus TIV in Thai popula

APA, Harvard, Vancouver, ISO, and other styles

8

Magnus, Anne, Vaughan Carr, Cathrine Mihalopoulos, Rob Carter, and Theo Vos. "Assessing Cost-Effectiveness of Drug Interventions for Schizophrenia." Australian & New Zealand Journal of Psychiatry 39, no. 1-2 (2005): 44–54. http://dx.doi.org/10.1080/j.1440-1614.2005.01509.x.

Full text

Abstract:

Objective: To assess from a health sector perspective the incremental cost-effectiveness of eight drug treatment scenarios for established schizophrenia. Method: Using a standardized methodology, costs and outcomes are modelled over the lifetime of prevalent cases of schizophrenia in Australia in 2000. A two-stage approach to assessment of health benefit is used. The first stage involves a quantitative analysis based on disability-adjusted life years (DALYs) averted, using best available evidence. The robustness of results is tested using probabilistic uncertainty analysis. The second stage in

APA, Harvard, Vancouver, ISO, and other styles

9

De Portu, Simona, Sabato Montella, Paolo Cortesi, et al. "Valutazioni economiche di atorvastatina in prevenzione secondaria: un aggiornamento." Farmeconomia. Health economics and therapeutic pathways 12, no. 2S (2011): 41–52. http://dx.doi.org/10.7175/fe.v12i2s.995.

Full text

Abstract:

Introduction: cardiovascular diseases are the most common reason of mortality and morbidity in the world, despite therapeutic interventions have improved patients’ prognosis in the last decades. Aggressive lipid lowering treatment with atorvastatin has demonstrated to be effective in preventing the occurrence of new cardiovascular events requiring hospitalizations, in patients previously affected by coronary syndromes. However, the increasing costs of managing cardiovascular diseases impose a careful analysis of the economic benefits of these therapies. Objective: to assess the economic sustai

APA, Harvard, Vancouver, ISO, and other styles

10

Charters, Brooke, Kelly Foster, Benjamin Lawton, et al. "On a quest to prevent harm and safeguard paediatric venous catheters – A randomized control trial protocol." Vascular Access 16, no. 3 (2022): 18–29. http://dx.doi.org/10.5737/va.v16i3.34.

Full text

Abstract:

Aim: This study will evaluate the most effective peripheral intravenous catheter securement in paediatric emergency departments to reduce catheter failure, healthcare costs, patient distress, and improve satisfaction. Design: A multisite, three-arm, parallel, superiority, randomized controlled trial of 506 children requiring peripheral intravenous catheter in the emergency department. The trial will be reported following CONSORT guidelines, is registered on the Australian New Zealand Clinical Trials Registry (ACTRN12619001026112) and ethics is approved via Children’s Health Queensland Hospital

APA, Harvard, Vancouver, ISO, and other styles

11

Eandi, Mario. "Costo-efficacia dell’amfotericina B liposomiale nella terapia dell’aspergillosi invasiva." Farmeconomia. Health economics and therapeutic pathways 5, no. 1 (2004): 47–61. http://dx.doi.org/10.7175/fe.v5i1.786.

Full text

Abstract:

Invasive aspergillosis (IA) is a common and life-threatening infectious complication of immune system depression. Amphotericin B deoxycholate (AMB-d) has been considered standard therapy for IA for over 40 years, despite the fact that success rates rarely exceed 40% and adverse effects are quite common. At present two more recent pharmacological agents are available for the treatment of IA: liposomal amphotericin B (L-AMB) and voriconazole (VOR). In this article, we present a pharmaco-economical study comparing the relative costeffectiveness of 5 alternative strategies in the treatment of inva

APA, Harvard, Vancouver, ISO, and other styles

12

Hammoumraoui, Nadir, Sid Ahmed Kherraf, Joaquin Mould-Quevedo, and Tarek A. Ismail. "The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria." Journal of Health Economics and Outcomes Research 1, no. 2 (2013): 184–99. http://dx.doi.org/10.36469/9865.

Full text

Abstract:

Background: Cyclooxygenase-2 inhibitors such as celecoxib are as effective as non-selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) in the treatment of osteoarthritis (OA), have fewer gastrointestinal side effects, but are more expensive. Objective: To evaluate the incremental cost-effectiveness ratio (ICER) of celecoxib versus ns-NSAIDs, with/without proton-pump inhibitor (PPI) co-therapy, for treating OA in Algeria. Methods: The National Institute for Health and Clinical Excellence (NICE) health economic model from UK, updated with relative risks of adverse events using CONDOR tria

APA, Harvard, Vancouver, ISO, and other styles

13

Ryagina, V. А., К. I. Matrenin, D. G. Shchurov, and Т. S. Teptsova. "Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention." FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15, no. 4 (2023): 407–17. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2022.156.

Full text

Abstract:

Objective: to assess the clinical and economic feasibility of ticagrelor in combination with acetylsalicylic acid (ASA) in comparison with clopidogrel in combination with ASA in patients with acute coronary syndrome (ACS), including both those who underwent, and those who did not undergo percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); and new oral anticoagulants (NOACs) in combination with clopidogrel in comparison with warfarin in combination with clopidogrel and ASA in patients with atrial fibrillation (AF) who underwent PCI; to identify the impact of the

APA, Harvard, Vancouver, ISO, and other styles

14

Camera, Alessandro, Carolina Ianuale, and Stefania Boccia. "Cost-effectiveness of HCV screening: a systematic review of the literature from 2007 to 2012." Epidemiology, Biostatistics, and Public Health 10, no. 3 (2022). http://dx.doi.org/10.2427/8767.

Full text

Abstract:

 Background: currently, 123-170 million people in the world are infected with Hepatitis C Virus (HCV) and 75% of them remain undiagnosed. HCV-positive individuals will develop Chronic Hepatitis C (CHC) or hepatocellular carcinoma (HCC) within 25 years in 20-30% of cases. Early detection of HCV has been demonstrated to increase quality-adjusted life years (QALY) and to improve the behaviour of the infected population. Current national policies usually recommend regular screenings only for at-risk populations. A systematic review of the recent evidence on long-term cost-effectiveness of HC

APA, Harvard, Vancouver, ISO, and other styles

15

Weiss, Manfred, Frank Grom, and Franz Porzsolt. "Costs of Additional Treatment Success (COATS) Based on Numbers Needed to Treat (NNT) is a Simplified Calculation Method to Facilitate Physicians Medical Decisions with Regards to Monetary Costs." October 31, 2012. https://doi.org/10.5281/zenodo.7861.

Full text

Abstract:

Aims: Due to limited resources, to provide a simple and transparent tool for physicians to facilitate budget-related, medical decisions in any patient. Study Design: Comparative study. Methodology: Several articles with topics referring to the 2008 ”Surviving Sepsis Campaign” guidelines in critically ill patients with varying effects on defined clinical endpoints were analyzed regarding the costs of additional treatment success (COATS). A simplified ICER = incremental cost-effectiveness ratio to assess COATS was expressed as the product of the number of patients needed to treat (NN

APA, Harvard, Vancouver, ISO, and other styles

16

Wong, W. W. L., M. Zargar, S. R. Berry, Y. J. Ko, M. Riesco-Martínez, and K. K. W. Chan. "Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer." Current Oncology 26, no. 5 (2019). http://dx.doi.org/10.3747/co.26.4843.

Full text

Abstract:

Background Evidence from a retrospective analysis of multiple large phase iii trials suggested that primary tumour location (ptl) in RAS wild-type metastatic colorectal cancer (wtRAS mcrc) might have predictive value with respect to response to drug therapies. Recent studies also show a potential preferential benefit for epidermal growth factor inhibitors (egfris) for left-sided tumours. In the present study, we aimed to determine the incremental costeffectiveness ratio (icer) for the first-line use of an egfri for patients with left-sided wtRAS mcrc.Methods We developed a state-transition mod

APA, Harvard, Vancouver, ISO, and other styles

17

Cheung, W. Y., E. A. Kornelsen, N. Mittmann, et al. "The economic impact of the transition from branded to generic oncology drugs." Current Oncology 26, no. 2 (2019). http://dx.doi.org/10.3747/co.26.4395.

Full text

Abstract:

Background Economic evaluations are an integral component of many clinical trials. Costs used in those analyses are based on the prices of branded drugs when they first enter the market. The effect of genericization on the costeffectiveness (ce) or cost–utility (cu) of an intervention is unknown because economic analyses are rarely updated using the costs of generic drugs.Methods We re-examined the ce or cu of regimens previously evaluated in Canadian Cancer Trials Group (cctg) studies that included prospective economic evaluations and where genericization has occurred or is anticipated in Can

APA, Harvard, Vancouver, ISO, and other styles

18

Eandi, Mario. "Costo-efficacia dell'amfotericina B liposomiale nella terapia dell'aspergillosi invasiva." June 13, 2016. https://doi.org/10.7175/fe.v5i1.786.

Full text

Abstract:

Invasive aspergillosis (IA) is a common and life-threatening infectious complication of immune system depression. Amphotericin B deoxycholate (AMB-d) has been considered standard therapy for IA for over 40 years, despite the fact that success rates rarely exceed 40% and adverse effects are quite common. At present two more recent pharmacological agents are available for the treatment of IA: liposomal amphotericin B (L-AMB) and voriconazole (VOR). In this article, we present a pharmaco-economical study comparing the relative costeffectiveness of 5 alternative strategies in the treatment of inva

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!